Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537394 · ClinicalTrials.gov registry record · Phase 3
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 517
- Enrollment target
NCT00537394 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 517 participants.
The verdict
NCT00537394, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 517 participants
- Enrollment target
Study Summary
The goal of anti-HIV therapy is to prevent HIV from replicating. Long-term control of HIV requires at least two anti-HIV drugs that are active against the virus. Drug resistance is a problem for many treatment-experienced, HIV-infected people. The purpose of this study was to determine the benefit of adding a nucleoside reverse transcriptase inhibitor (NRTI) to a new anti-HIV drug regimen for the suppression of HIV.
Interventions
- DRUG Etravirine
- DRUG Raltegravir
- DRUG Darunavir
- DRUG Enfuvirtide
- DRUG Tipranavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 517 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537394
The ClinicalTrials.gov registry entry for NCT00537394 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 517 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Etravirine is the first listed.
NCT00537394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537394 about?
NCT00537394 is a clinical study titled "Optimizing Treatment for Treatment-Experienced, HIV-Infected People". The goal of anti-HIV therapy is to prevent HIV from replicating. Long-term control of HIV requires at least two anti-HIV drugs that are active against the virus. Drug resistance is a problem for many treatment-experienced, HIV-infected people. The purpose of this study was to determine the benefit o...
What is the current status of trial NCT00537394?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 517 participants. The study started on 2008-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00537394?
The interventions under investigation include: Etravirine (DRUG), Raltegravir (DRUG), Darunavir (DRUG), Enfuvirtide (DRUG), Tipranavir (DRUG).
Who is sponsoring clinical trial NCT00537394?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.